NEW YORK, April 12, 2016 -- Pomerantz LLP announces that the United States District Court for the Southern District of New York has approved the following announcement of a proposed class action settlement that would benefit purchasers of common stock of Altair Nanotechnologies, Inc. (OTCMKTS:ALTI):
NOTICE OF PENDENCY AND SETTLEMENT OF CLASS ACTION
TO: All persons or entities who purchased or otherwise acquired the common stock of Altair Nanotechnologies Inc. between May 15, 2013 and September 25, 2014.
A hearing (the “Settlement Hearing”) shall be held before the Honorable Analisa Torres of the Southern District of New York in the Daniel Patrick Moynihan United States Courthouse, Courtroom 15D, 500 Pearl St., New York, NY 10007-1312, on May 25, 2016 at 4:00 p.m. At the Settlement Hearing, the Court will consider whether (1) to permanently certify a class (the “Class”), for settlement purposes only, of all persons or entities who purchased or otherwise acquired the common stock of Altair Nanotechnologies Inc. (“Altair”) between May 15, 2013 and September 25, 2014 (the “Class Period”); (2) to approve as fair, reasonable, and adequate the proposed settlement of this action (the “Action”) in exchange for $1.5 million; (3) to dismiss with prejudice the Action and to enter judgment releasing the Settled Claims against the Defendants and Released Parties; and (4) to approve Lead Counsel’s application for payment of attorneys’ fees and reimbursement of costs and expenses.
If you purchased or otherwise acquired Altair common stock during the Class Period, you will be bound by the Settlement unless you send a letter stating that you “request exclusion from the Class in the Altair Nanotechnologies Securities Litigation” to be received by May 11, 2016 to: Altair Nanotechnologies Securities Litigation, c/o Strategic Claims Services, Claims Administrator, P.O. Box 230, 600 N. Jackson Street, Suite 3, Media, PA 19063. If you are a member of the Class, in order to share in the distribution of the Net Settlement Fund, you must submit a Proof of Claim and Release postmarked no later than May 30, 2016 to the Claims Administrator, establishing that you are entitled to recovery.
If you are a Class Member and do not exclude yourself, you can object to the Settlement by filing a signed letter with the Court saying that you object to the proposed Settlement in the Altair Nanotechnologies Securities Litigation. Your objection must be filed with the Court and mailed or delivered to each of the following addresses and received no later than May 11, 2016:
| COURT | LEAD COUNSEL | SETTLING DEFENDANTS’ COUNSEL |
| Clerk of the Court United States District Court Southern District of New York Daniel Patrick Moynihan United States Courthouse 500 Pearl St. New York, NY 10007-1312 | Jeremy A. Lieberman POMERANTZ LLP 600 Third Avenue 20th Floor New York, NY 10016 | William M. Regan KATTEN MUCHIN ROSENMAN LLP 575 Madison Avenue New York, NY 10022 |
Any objection must include: (1) a written notice of an intention to appear (if you intend to appear); (2) proof of ownership of Altair common stock and membership in the Class; (3) a detailed statement of your objections to any matters before the Court; and (4) the grounds therefor or the reasons that wish to appear and be heard, as well as all documents or writings you wish the Court to consider.
For copies of the complete settlement documents, please visit the Claims Administrator’s website at https://www.strategicclaims.net/altair or contact the Claims Administrator toll-free at (866) 274-4004.
Any questions regarding the Settlement should be directed to Lead Counsel. Please do not contact the Court or the Clerk’s Office or Defendants’ Counsel regarding this Notice.
| Dated: February 19, 2016 | BY ORDER OF THE COURT | |||
| UNITED STATES DISTRICT COURT | ||||
| SOUTHERN DISTRICT OF NEW YORK |


Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Italy Fines Apple €98.6 Million Over App Store Dominance
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 



